Affiliation:
1. Key Laboratory of Molecular Pharmacology & Drug Evaluation, School of Pharmacy, Yantai University, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System & Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, PR China
Abstract
Aim: Evolocumab is a human monoclonal antibody used in the treatment of cardiovascular diseases, which targeted proprotein convertase subtilisin kexin type 9. To accurately quantify free (including partially bound) and total evolocumab concentrations in serum, indirect and generic ELISA methods were developed and validated in rat serum. Results: Indirect ELISA was accurate and precise over the concentration range of 23.4–1500 ng/ml, and the method was validated for selectivity, specificity, accuracy and precision, dilution linearity, parallelism and stability. Similarly, generic antihuman IgG ELISA method was validated for selectivity, accuracy and precision, and dilution linearity. Moreover, incurred sample reanalysis were carried out for the above two methods, and the percent difference met the acceptable criteria. Conclusion: The validated methods can be effectively used to evaluate pharmacokinetics of free and total evolocumab after subcutaneous administration of evolocumab to rats.
Subject
Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry
Reference21 articles.
1. Familial Hypercholesterolemia: Present and Future Management
2. Hypercholesterolemia: The role of PCSK9
3. The PCSK9 decade
4. PCSK9 inhibition in the management of familial hypercholesterolemia
5. Repatha. Full prescribing information, Repatha (evolocumab). Reference ID 3812424[J]. (2015) https://www.ema.europa.eu/documents/product-information/repatha-epar-product-information_en.pdf